Oscient Pharmaceuticals to Present at Wells Fargo Securities 2005 Healthcare Conference; Webcast of presentation available Tuesday, March 1, 2005 at 9:30 AM ET.WALTHAM, Mass. -- Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the Wells Fargo Securities 2005 Healthcare Conference on March 1, 2005 in New York. The Company's President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Steven Rauscher, will provide an overview of the Company as well as an update on the market performance of FACTIVE Fac´tive a. 1. Making; having power to make. (R) (gemifloxacin mesylate) tablets, the Company's lead product. The presentation will begin at 9:30 AM ET on Tuesday and will be webcast through the Company's website at www.oscient.com. An archive of the webcast will also be available for 90 days. About Oscient Pharmaceuticals Oscient Pharmaceuticals Corporation is a biopharmaceutical company committed to the clinical development and commercialization of novel therapeutics to address unmet medical needs. The Company is marketing FACTIVE (R) (gemifloxacin mesylate) tablets, approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. In addition to the oral tablet form, Oscient Pharmaceuticals is developing an investigational FACTIVE intravenous formulation for hospitalized patients. The Company has a novel antibiotic candidate, Ramoplanin, in advanced clinical development for the treatment of Clostridium clostridium Any of the rod-shaped, usually gram-positive bacteria (see gram stain) that make up the genus Clostridium. They are found in soil, water, and the intestinal tracts of humans and other animals. Some species grow only in the complete absence of oxygen. difficile-associated diarrhea (CDAD CDAD Clostridium Difficile-Associated Diarrhea CDAD Component Data Administrator ). The Company's preclinical program includes an oral peptide deformylase (PDF (Portable Document Format) The de facto standard for document publishing from Adobe. On the Web, there are countless brochures, data sheets, white papers and technical manuals in the PDF format. ) inhibitor series, under preclinical development for community-based respiratory tract infections. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion